Warner-Lambert acquired Agouron Pharmaceuticals in an all-stock merger valued at approximately $2.1B, with each Agouron share exchanged for roughly $60 of Warner-Lambert stock. Announced in January 1999, the deal closed on May 17, 1999. It gave Warner-Lambert the HIV protease inhibitor Viracept (nelfinavir) and Agouron's oncology discovery pipeline.